Synergy Pharmaceuticals Inc  

(Public, NASDAQ:SGYP)   Watch this stock  
Find more results for OTC:SGYP
4.31
+0.20 (4.74%)
Mar 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.12 - 4.35
52 week 2.45 - 5.52
Open 4.20
Vol / Avg. 3.22M/2.01M
Mkt cap 397.55M
P/E     -
Div/yield     -
EPS -1.01
Shares 96.61M
Beta 0.17
Inst. own 41%
Mar 16, 2015
Q4 2014 Synergy Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -97.66% -66.95%
Return on average equity -1782.11% -381.39%
Employees 35 -
CDP Score - -

Address

SUITE 2012, 420 LEXINGTON AVENUE
NEW YORK, NY 10170
United States - Map
+1-212-2970010 (Phone)
+1-212-2970019 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Synergy Pharmaceuticals Inc., (Synergy) is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company is engaged in the field of human therapeutics. The Company�s products include plecanatide, SP-333 and FV-100. Plecanatide is a guanylate cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation (CIC), and constipation predominant irritable bowel syndrome (IBS-C). The Company is also developing SP-333, a second generation GC-C receptor agonist for the treatment of inflammatory bowel diseases, such as ulcerative colitis (UC). The Company is developing a second-generation GC-C receptor agonist, SP-333, for the treatment of opioid induced constipation (OIC), and for ulcerative colitis (UC), an inflammatory bowel disease. The Company�s subsidiaries include Synergy Advanced Pharmaceuticals, Inc., IgX, Ltd and ContraVir Pharmaceuticals, Inc.

Officers and directors

Gary S. Jacob Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 67
Bio & Compensation  - Reuters
Bernard F. Denoyer CPA Senior Vice President - Finance, Secretary, IR Contact Officer
Age: 67
Bio & Compensation  - Reuters
Paul Eng Ph.D. Senior Vice President - Drug Development
Bio & Compensation  - Reuters
Marino Garcia Senior Vice President - Corporate Development
Bio & Compensation  - Reuters
Kunwar Shailubhai Ph.D. Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Thomas H. Adams Jr., Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 67
Bio & Compensation  - Reuters
Alan F. Joslyn Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Christopher McGuigan Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Melvin K. Spigelman M.D. Independent Director
Age: 66
Bio & Compensation  - Reuters